2-(3-苯甲酰基苯基)丙酸钠 | 57495-14-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(3-苯甲酰基苯基)丙酸钠
• 中文别名: 酮洛芬钠
• CAS: 57495-14-4
• 化学式: C16H14NaO3
• 分子量: 277.27
• InChiKey: DPAWCKAUNQMBJU-UHFFFAOYSA-N

物化性质

• 熔点：
  184 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.72
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• HYALURONIC ACID DERIVATIVE AND DRUG CONTAINING THE SAME
  申请人：Seikagaku Corporation

  公开号：EP3363463A2

  公开（公告）日：2018-08-22

  The present invention relates to a hyaluronic acid derivative in which an anti-inflammatory drug is bound via a covalent bond, wherein the structure of the hyaluronic acid derivative is represented by following formula (4) or (5):          HA-SP-NSAID     (4)          HA-SP-DMARD     (5) wherein HA represents a hyaluronic acid chain; SP represents a spacer residue; NSAID represents a non-steroidal anti-inflammatory drug residue, DMARD represents a disease-modifying anti-rheumatic drug residue, and - represents the covalent bond, wherein the spacer binds to a carboxyl group of the hyaluronic acid via an amide bond and the anti-inflammatory drug selected from non-steroidal anti-inflammatory drugs and disease-modifying anti-rheumatic drugs binds to the spacer via an ester bond, an amide bond or a thioester bond.

  本发明涉及一种透明质酸衍生物，其中通过共价键结合了一种抗炎药物，其中透明质酸衍生物的结构由以下公式（4）或（5）表示：          HA-SP-NSAID     (4)          HA-SP-DMARD     (5) 其中HA代表透明质酸链；SP代表间隔基团；NSAID代表非甾体抗炎药残基，DMARD代表改善疾病的抗风湿药物残基，-代表共价键，其中间隔基通过酰胺键与透明质酸的羧基结合，并且选自非甾体抗炎药物和改善疾病的抗风湿药物的抗炎药物通过酯键、酰胺键或硫酯键与间隔基结合。
• Prodrugs of non-steroidal anti-inflammatory and carboxylic acid containing compounds
  申请人：——

  公开号：US20030060465A1

  公开（公告）日：2003-03-27

  Compounds of the formula: RC(O)O-spacer-OC(O)R′, wherein (i) RC(O)— is the acyl residue of an NSAID or other pharmaceutically active agent bearing a carboxylic acid function, (ii) spacer is C n alkyl, (iii) n is from 1 to 6, and (iv) R′ is substituted or unsubstituted heteroaryl or heterocycle, and pharmaceutical compositions thereof.

  式为：RC（O）O-间隔-OC（O）R′的化合物，其中（i）RC（O）—是非甾体类抗炎药或其他具有羧酸功能的药物活性剂的酰基残基，（ii）间隔是Cn烷基，（iii）n为1至6，（iv）R′为取代或未取代的杂芳基或杂环基，以及其药物组合物。
• [EN] PROCESS FOR PREPARING NITROOXYALKYL SUBSTITUTED ESTERS OF CARBOXYLIC ACIDS, INTERMEDIATES USEFUL IN SAID PROCESS AND PREPARATION THEREOF<br/>[FR] PROCEDE DE PREPARATION D'ESTERS D'ACIDES CARBOXYLIQUES A SUBSTITUTION NITROOXYALKYLE, INTERMEDIAIRES UTILISES DANS LEDIT PROCEDE ET LEUR PREPARATION
  申请人：NICOX SA

  公开号：WO2004020385A1

  公开（公告）日：2004-03-11

  The present invention refers to a process for preparing a compound of general formula (A), as reported in the description, wherein R is a radical of a drug and R1-R12 are hydrogen or alkyl groups, m, n, o, q, r and s are each independently an integer from 0 to 6, and p is 0 or 1, and X is O, S, SO, SO2, NR13 or PR13 or an aryl, heteroaryl group, said process comprising reacting a compound of formula (B) R-COOZ (B) wherein R is as defined above and Z is hydrogen or a cation selected from: Li+, Na+, K+, Ca++, Mg++, tetralkylammonium, tetralkylphosphonium, with a compound of formula (C), as reported in the description, wherein R1-R12 and m, n, o, p, q, r, s are as defined above and Y is a suitable leaving group.

  本发明涉及一种制备一般式(A)化合物的过程，如描述中所述，其中R是药物的基团，R1-R12是氢或烷基基团，m、n、o、q、r和s分别是0到6之间的整数，p为0或1，X为O、S、SO、SO2、NR13或PR13或芳基、杂环芳基基团，所述过程包括将一种一般式(B)的化合物与一种一般式(C)的化合物反应，其中R为上述定义，Z为氢或从Li+、Na+、K+、Ca++、Mg++、四烷基铵、四烷基磷酸盐中选择的阳离子，R1-R12和m、n、o、p、q、r、s如上所述，Y为适当的离去基团。
• Prodrugs of non-steroidal anti-inflammatory and carboxylic acid containing compound
  申请人：Specialized Pharmaceutical Research Ltd. Co.

  公开号：EP1231209A1

  公开（公告）日：2002-08-14

  Compounds of the formula: RC(O)O-spacer-OC(O)R' are claimed, wherein (i) RC(O)- is the acyl residue of an NSAID or other pharmaceutically active agent bearing a carboxylic acid function, (ii) spacer is Cn alkyl, (iii) n is from 1 to 6, and (iv) R' is substituted or unsubstituted heteroaryl or heterocycle, and pharmaceutical compositions thereof. The compounds are prodrugs of NSAIDS and can be used to treat inflammation.

  该公式化合物为：RC(O)O-间隔-OC(O)R'，其中（i）RC(O)-是非甾体抗炎药物或其他具有羧酸功能的药用活性剂的酰基残基，（ii）间隔是Cn烷基，（iii）n为1至6，（iv）R'是取代或未取代的杂环芳基或杂环烃基，以及其药用组合物。这些化合物是非甾体抗炎药物的前药，可用于治疗炎症。
• [EN] CO-CRYSTAL OF KETOPROFEN, COMPOSITIONS COMPRISING THE SAME, PROCESS OF PRODUCING THE SAME, AND USES THEREOF<br/>[FR] CO-CRISTAL DE KÉTOPROFÈNE, COMPOSITIONS LE COMPRENANT, SON PROCÉDÉ DE PRODUCTION ET SES UTILISATIONS
  申请人：DOMPE FARM SPA

  公开号：WO2020126088A1

  公开（公告）日：2020-06-25

  The present invention refers to a co-crystal of Ketoprofen Lysine named Form 1, a pharmaceutical composition comprising said co-crystal, a process for its production and to its use in the treatment of pain and inflammatory diseases.

  本发明涉及一种称为Form 1的酮酸赖氨酸共晶体，包括该共晶体的制药组合物，其制备过程以及在治疗疼痛和炎症性疾病中的使用。